SG Americas Securities’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-122,922
| Closed | -$2.63M | – | 3417 |
|
|
2026
Q1 | $2.63M | Sell |
122,922
-227,170
| -65% | -$3.2M | ﹤0.01% | 1268 |
|
|
2025
Q4 | $3.26M | Buy |
350,092
+323,747
| +1,229% | +$2.7M | ﹤0.01% | 1284 |
|
|
2025
Q3 | $186K | Buy |
+26,345
| New | +$181K | ﹤0.01% | 2786 |
|
|
2025
Q2 | – | Sell |
-34,409
| Closed | -$273K | – | 3079 |
|
|
2025
Q1 | $273K | Sell |
34,409
-33,965
| -50% | -$366K | ﹤0.01% | 2290 |
|
|
2024
Q4 | $866K | Buy |
+68,374
| New | +$951K | ﹤0.01% | 931 |
|
|
2024
Q3 | – | Sell |
-8,222
| Closed | -$113K | – | 3453 |
|
|
2024
Q2 | $113K | Buy |
+8,222
| New | +$120K | ﹤0.01% | 2476 |
|
|
2024
Q1 | – | Sell |
-64,692
| Closed | -$945K | – | 3065 |
|
|
2023
Q4 | $945K | Buy |
64,692
+27,712
| +75% | +$336K | 0.01% | 1057 |
|
|
2023
Q3 | $454K | Buy |
36,980
+13,683
| +59% | +$178K | 0.01% | 1838 |
|
|
2023
Q2 | $278K | Buy |
23,297
+6,140
| +36% | +$80.2K | ﹤0.01% | 1646 |
|
|
2023
Q1 | $229K | Buy |
17,157
+4,018
| +31% | +$78.5K | ﹤0.01% | 2325 |
|
|
2022
Q4 | $283K | Buy |
13,139
+3,519
| +37% | +$72.2K | ﹤0.01% | 1966 |
|
|
2022
Q3 | $193K | Buy |
9,620
+174
| +2% | +$3.7K | ﹤0.01% | 2354 |
|
|
2022
Q2 | $169K | Buy |
+9,446
| New | +$97.5K | ﹤0.01% | 2784 |
|
Other funds holding DAWN
SG Americas Securities's DAWN Position: Q2 2026 in Review
SG Americas Securities sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 122,922 shares — an estimated $2.63M sold.
SG Americas Securities first reported a position in DAWN in Q2 2022 and held it in 13 quarters. The position peaked at $3.26M in Q4 2025. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- SG Americas Securities reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- SG Americas Securities sold 122,922 Day One Biopharmaceuticals shares in Q2 2026, an estimated $2.63M.
- SG Americas Securities first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 13 quarters.
- SG Americas Securities's Day One Biopharmaceuticals position peaked at $3.26M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.